Afficher la notice abrégée

Characteristics of severe asthma patients included in the French Palomb Cohort

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorJESTIN-GUYON, Nolwenn
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorOUAALAYA, El Hassane
dc.contributor.authorOZIER, Annaig
dc.contributor.authorNOCENT, Cecilia
dc.contributor.authorBERNADY, Alain
dc.contributor.authorNGUYEN, Laurent
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBERTEAUD, Emilie
dc.contributor.authorDUPUY-GRASSET, Magali
dc.contributor.authorLE GUILLOU, Frederic
dc.contributor.authorMELLONI, Boris
dc.contributor.authorPORTEL, Laurent
dc.contributor.authorPRUD'HOMME, Anne
dc.contributor.authorDIDIER, Alain
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOLIMARD, Mathieu
dc.contributor.authorGUILLEMINAULT, Laurent
dc.contributor.authorRAHERISON-SEMJEN, Chantal
dc.date.accessioned2024-02-15T12:51:01Z
dc.date.available2024-02-15T12:51:01Z
dc.date.issued2023-09-09
dc.date.conference2023-09-09
dc.identifier.issn0903-1936en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/188162
dc.description.abstractEnBackground: The prevalence of severe asthma among asthmatic patients is estimated between 5-10% in France. The aim of this work was to describe clinical features of patients included in the French Severe Asthma Palomb cohort. Methods: Patients followed in a real-life context by pulmonologists located in 2 regions since 2019. Inclusion criteria: 1) ⩾18 years-old, 2) >6 months follow-up before inclusion for severe asthma, (GINA, 2019) 3) combination of ICS and LABA and anticholinergic, associated with 4) OCS, anti-IgE based treatment, anti-IL5, anti-RIL5, anti-IL4, anti-IL13, thermoplasty. Results: In January 2023, 214 patients were included. Mean age was 55.1 years old (±16.4). 61.7% were female, 30.0% had a BMI⩾30 (morbid/severe obesity), 29.3% were previous smokers and 4.8% current smokers. 61.4% had an onset of asthma symptoms after the age of 15 and 21.8% had a history of acute severe asthma. 36.8% had dyspnea (mMRC⩾2) and 23.8% had chronic cough (>8 weeks). During the 12 months before inclusion, 25.2% had at least 2 exacerbations (having required a general corticotherapy or an increase in ICS treatment). 29.0% had chronic rhinitis, 22.9% gastro-esophageal reflux disease, 19.2% chronic rhinosinusitis, 14.0% anxiety, 13.6% blood hypertension and 13.1% sleep apnea syndrome. Regarding phenotypes: 46.0% were eosinophilic with allergy and 32.1% were eosinophilic without allergy. 135 patients were already on a biotherapy treatment at inclusion and 26 had a biotherapy introduced at inclusion. Conclusion: These are preliminary results of an observatory of patients followed with severe asthma in the French medical framework. Sponsors: Bordeaux University Foundation, AstraZeneca, Chiesi, GSK, Novartis, Sanofi.
dc.language.isoENen_US
dc.subject.enAsthma management
dc.subject.enEnvironment
dc.subject.enSevere asthma
dc.title.enCharacteristics of severe asthma patients included in the French Palomb Cohort
dc.typeCommunication dans un congrèsen_US
dc.identifier.doi10.1183/13993003.congress-2023.PA4432en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.pagePA4432en_US
bordeaux.volume62en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issuesuppl 67en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.conference.titlethe ERS International Congress 2023en_US
bordeaux.countryiten_US
bordeaux.title.proceedingERS International Congress 2023 abstractsen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.conference.cityMilanen_US
bordeaux.identifier.funderIDAstraZenecaen_US
bordeaux.identifier.funderIDChiesi Farmaceuticien_US
bordeaux.identifier.funderIDNovartisen_US
bordeaux.identifier.funderIDSanofien_US
hal.identifierhal-04459617
hal.version1
hal.date.transferred2024-02-15T12:51:05Z
hal.invitedouien_US
hal.proceedingsouien_US
hal.conference.organizerThe European Respiratory Society (ERS)en_US
hal.conference.end2023-09-13
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.date=2023-09-09&rft.volume=62&rft.issue=suppl%2067&rft.spage=PA4432&rft.epage=PA4432&rft.eissn=0903-1936&rft.issn=0903-1936&rft.au=JESTIN-GUYON,%20Nolwenn&OUAALAYA,%20El%20Hassane&OZIER,%20Annaig&NOCENT,%20Cecilia&BERNADY,%20Alain&rft.genre=unknown


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée